<DOC>
	<DOCNO>NCT01148420</DOCNO>
	<brief_summary>The purpose study investigate effectiveness acceptability high dose MPA ( 20mg oral 3 time day ) 3 day combine injection DMPA 150 mg intramuscularly treatment acute heavy , prolonged uterine bleed identify eligible outpatient management</brief_summary>
	<brief_title>DMPA &amp; High Dose Oral Progestin ( MPA ) Tablets Outpatient Treatment Acute Excessive Vaginal Bleeding</brief_title>
	<detailed_description>Excessive vaginal bleeding frequent problem reproductive age woman account many office emergency room visit . This bleeding cause cancer , endocrinologic problem , liver failure , benign tumor uterus , cervix , well hormone imbalance , anovulatory cycling . Even though excessive vaginal bleeding common , little research way manage . For non-pregnant woman stable vital sign hemorrhage experience severe anemia , outpatient therapy generally attempt . Textbooks recommend treatment high dose oral contraceptive pill ( one tablet orally 2 time day 5 day ) . Recently , Munro et al publish small study use high dos oral progestin ( MPA 20mg 3 time daily 7 day one daily 21 day ) . The median time bleed cessation 3 day . Munro report difficulty enrol adequate number patient achieve statistical significance . The investigator propose pilot project study clinical response new hormonal therapy blend high dose oral therapy longer act injectable progestin . The pilot clinical trial design study 50 woman bleed whose treatment amenable outpatient therapy . Routine care provide woman approach study enrollment . This study , therefore , design provide short term proven therapy 20 mg MPA tablets 3 time day 3 day combine injectable progestin ( DMPA ) last 3 month . Patients call within 24 hour 48 hour follow first study visit ascertain bleeding status use medication , well significant side effect may experience . Patients ask return clinic day 3 repeat hemoglobin interval history . Those woman still bleed day 3 contact day 5 . The primary outcome measure part study time elapse slow acute bleed well compliance study medication . The patient 's time complete cessation bleed percent woman complete bleed cessation also calculate . Results biopsies do randomization also evaluate see influence study outcome . From degree response see pilot study , large clinical trial may design .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Age 18 50 Nonpregnant Candidate outpatient management Able understand follow instruction Vital sign stable No severe anemia No medical condition require transfusion Pregnancy Breast cancer current last 5 year Allergy MPA DMPA Previous hormonal therapy Unstable vital sign Bleeding excessive enough require surgical therapy hospital admission Desire pregnancy next 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>